Mark Bamforth Overview

  • Investor Type
  • Angel

  • Investments
  • 9

  • Portfolio
  • 6

  • Exits
  • 3

Exits

Mark Bamforth General Information

Description

Mr. Mark Bamforth serves as Investor Director at Pneumagen. He serves as Executive Chairman at Kincellis Advanced Therapies. He served as Executive Chair of the Board at Kincell Bio. Mr. Bamforth is a Co-Founder and serves as Chief Executive Officer at Thairm Bio. He serves as Chief Executive Officer & President at Centocor Biologics. He also serves as Executive Advisor at Ampersand Capital Partners. He serves as Executive Chairman at Kineticos Life Sciences Management. He serves as Board Member at Continuus Pharmaceuticals and EnteroBiotix. He serves as a Non-Executive Director at Pneumagen. He served as Board Member and Advisor at Inceptor Bio. He co-founded and served as Chief Executive Officer & Executive Chairman at Arranta Bio. He co-founded and served as Chief Executive Officer and President at Brammer Biopharmaceuticals. He serves as a Senior Vice President of Genzyme Molecular Oncology. He is responsible for product supply from Genzyme's twelve GMP manufacturing sites located in Europe, the USA, and Australia, which produce some 20 commercial, regulated products using a biological, small molecule, therapeutic polymer, cell, tissue, and biomaterial device technologies. He served as the Senior Vice President of Corporate Operations and Pharmaceuticals of Genzyme Corporation since May 2004. He served as Senior Vice President of Corporate Operations at Genzyme Oncology. from May 2001 to May 2004. He joined Genzyme in 1988 as Vice President and General Manager of Genzyme's operations in the United Kingdom. He was responsible for the centralized support functions of Quality & Technical Operations and Materials Management which support all of Genzyme's sites and businesses, including management of the capacity strategy with an investment of $300-400M p.a. to develop internal manufacturing capacity and infrastructure. In addition, he is responsible for the Pharmaceutical Business Unit which has a manufacturing operation in Liestal, Switzerland, and sells specialty chemicals and drug delivery technologies to the biotechnology and pharmaceutical industry and manufactures clinical materials for Genzyme development products. Before joining Genzyme in 1988, he served as a Drilling Engineer in the North Sea offshore oil industry and then as a Chemical Engineer in the whisky industry in Scotland. He serves as a Member of the Advisory Board of Scottish Development International. He serves on the Massachusetts Biotechnology Council Board, University College London's (UCL) Department of Biochemical Engineering's Advisory Board, and on Scottish Enterprise's International Advisory Board. He has a BSc. Honors in Chemical Engineering from Strathclyde University and an MBA from Henley Business School. He serves as Operating Partner at Ampersand Capital Partners.

Business Details

Primary Investor Type
Angel (individual)
Corporate Office
  • 4766 La Guardia Drive
  • Berkeley, MO 63134
  • United States
+1 (314)

Mark Bamforth Investments (9)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Thymmune 01-Mar-2023 Early Stage VC Biotechnology Generating Revenue
Dxcover 23-Jan-2023 Diagnostic Equipment Generating Revenue
PneumoWave 12-Jan-2023 Other Healthcare Technology Systems Out of Business
AutonomUS 01-Oct-2022 Surgical Devices Generating Revenue
Celtic Renewables 22-Jul-2022 Energy Production Generating Revenue
Talking Medicines 31-Jan-2022 Other Healthcare Technology Systems Generating Revenue
CANbridge Pharma 21-May-2021 Pharmaceuticals Generating Revenue
Continuus Pharmaceuticals 26-Aug-2019 Later Stage VC Machinery (B2B) Generating Revenue
EnteroBiotix 29-May-2019 Seed Round Drug Discovery Clinical Trials - Phase 2

Mark Bamforth Exits (3)

Company Name Exit Date Exit Type Exit Size
Thymmune 02-Jul-2026 Merger/Acquisition
PneumoWave 17-May-2026
CANbridge Pharma 10-Dec-2021

Mark Bamforth Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Mark Bamforth Co-Investors (30)

Name With Exits Lead Partner Series Industry
Scottish Enterprise 4 Series chart Industry bar
SIS Ventures Series chart Industry bar
Equity Gap Series chart Industry bar
The Wyss Foundation Series chart Industry bar
University of Strathclyde Endowment Series chart Industry bar

Mark Bamforth FAQs

  • Who is Mark Bamforth?

    Mark Bamforth is an angel Investor who has made 9 investments.

  • What kind of investor is Mark Bamforth?

    Mark Bamforth is an angel investor.

  • What does Mark Bamforth do?

    As an angel investor, Mark Bamforth invests personal money into promising companies, typically in exchange for equity.

  • How many board seats does Mark Bamforth hold?

    Mark Bamforth holds a board seat in Continuus Pharmaceuticals.

  • What has Mark Bamforth invested in?

    Mark Bamforth has made numerous investments in companies like Thymmune, Dxcover, and PneumoWave within the Biotechnology, Diagnostic Equipment, and Healthcare Technology Systems industries.

  • What has Mark Bamforth invested in recently?

    Mark Bamforth's latest investment was on 01-Mar-2023 in Thymmune, a company within the Biotechnology industry.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process